Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia.

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy.
• The development of diffuse histiocytic lymphoma (DH) in patients with CLL is a rare but serious complication.
• Understanding the characteristics and outcomes of this dual diagnosis is crucial for patient management.

Purpose of the Study:

• To describe the clinical presentation, incidence, and outcomes of patients with CLL who develop DH.
• To investigate the potential relationship between CLL and DH, including blastic transformation or a second malignancy.
• To hypothesize potential therapeutic strategies for improving survival in this patient cohort.

Main Methods:

• Retrospective case series analysis of nine patients with a confirmed diagnosis of both CLL and DH.
• Review of clinical records, including patient history, symptoms, laboratory findings, and treatment data.
• Analysis of survival data following the diagnosis of DH.

Main Results:

• An incidence of at least 3.3% for DH developing in CLL patients was observed.
• DH occurred after a median of 2 years of pre-existing CLL.
• Abdominal symptoms and organomegaly (lymph nodes, spleen, liver) were common presentations of DH.
• No consistent laboratory abnormalities were noted at DH onset.
• Four cases of localized DH were identified.
• A median survival of 2 months from DH diagnosis was observed, with eight of nine patients deceased.

Conclusions:

• The development of DH in CLL patients is associated with a very poor prognosis and short survival.
• The exact nature of DH in CLL patients (blastic transformation vs. second malignancy) remains uncertain.
• Current therapeutic approaches for DH may warrant investigation for potential survival benefits in this specific patient population.